Monica Gray

Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) Rockets on Open!

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) stock gapped up to open the trading day on news that The Safariland Group announced a newly formed partnership with Digital Ally® for an exclusive distribution agreement of Digital Ally’s VuLink® car based auto-activation system. Twenty minutes into trading, DGLY shares have traded 2.4 million shares versus the listed daily average of just 47,300 – or 500 times the average!

digital ally, DGLY

Stan Ross, CEO of Digital Ally, Inc. (NASDAQ:DGLY) “We are pleased that others are recognizing the importance and value of our products and intellectual properties, especially our patented VuLink auto-activation technology. We are excited to partner with VIEVU to give them the products and technology they need to bring this capability to VIEVU’s customers.”

VuLink System

The Digital Ally VuLink system wirelessly sends a signal to automatically activate the user’s body-worn camera based on various actions with the vehicle, such as a siren being activated, lights being turned on, or a door opening. The VuLink system, when connected to the VIEVU body-worn camera can improve consistency in camera activation by automatically turning on the officer’s camera based on agency-selected vehicle triggers. The automatic activation will significantly reduce situations where body-worn camera footage is not available because an the user forgot to activate the camera.

DGLY Stock Action

Digital Ally, Inc. (NASDAQ:DGLY) stock trade near $6 in February before beginning a long, consistent slide that saw the shares touch their 52-week low of $2.15. Yesterday DLGY shares closed at $2.20 then opened today at $3.05 on the news detailed above. The inter-day high, so far, of $3.50 was hit in the first ten minutes and then the sellers stepped in.

Prior to today’s price action, DGLY shares have been underperforming for investors. They have been down over 47% year-to-date and lost 20% in the past month alone. Despite the poor performance over 2017, two analysts have a “Strong Buy” on DGLY stock with a consensus price target of $8.50.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DGLY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Design Corp (NASDAQ:IMDZ) Awarded Orphan Drug Designation

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 16% after the clinical stage company announced that the European Medicine Agency had granted its immunotherapy, G100, for non-Hodgkin’s lymphoma Orphan Drug Designation. The EMA designation is normally assigned to products targeting the treatment of rare medical conditions with prevalence of not more than 5 in 10,000 people.

The designation accords Immune Design Corp (NASDAQ:IMDZ) a string of benefits not limited to reduced fees for regulatory activities. The company also stands to enjoy protocol assistance when it comes to clinical trials. In addition, the clinical stage immunotherapy company will be granted 10 years of market exclusivity upon approval by regulators in the Union.

The company’s lead drug for the treatment of non-Hodgkin’s lymphoma has also been granted Orphan Drug Designation in the U.S by the Food and Drug Administration. Developed from Immune Design Corp (NASDAQ:IMDZ)’s GLAAS discovery platform, the candidate product is designed to activate innate and adaptive immunity in the tumor microenvironment.

IMDZ Stock Performance

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) free fall in the market shows no signs of slowing down as the stock has shed more than 40% in market value since the start of the month. The stock is currently trading at levels last seen at the start of the year.

Declining investor’s sentiments on the stock follows reports that the company plans to initiate a Phase 3 study of cancer vaccine candidate CMB305 in NY-ESO-1. The timing of the study, slated for mid-2018, appears to have spooked investors. The stock has also been downgraded by analysts at Wells Fargo to a ‘Neutral’ – seen as another cause for alarm among investors.

Immune Design Pipeline

CMB305 is one of Immune Design primary candidates currently in multiple clinical trials in patients with soft tissue sarcoma. The product is being investigated as a monotherapy and in combination with Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s RHHBY Tecentriq.

“The trial will have progression-free survival (PFS) followed by overall survival (OS) as co-primary endpoints. If the PFS endpoint is successful, the FDA offered that it may support full approval of CMB305. Depending on the rate of events, final PFS analysis may occur as early as 24 months from the first patient dosed,” Immune Design in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Alcobra Ltd (NASDAQ:ADHD) Makes Strong Move Up

Alcobra Ltd (NASDAQ:ADHD)

Israeli-based Alcobra Ltd (NASDAQ:ADHD) stock gained almost 19% after it was announced that the biotechnology company had entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). Volume exploded and was almost 100 times the daily average by the end of trading.

NASDAQ:ADHD

Deal Details

An Alcobra subsidiary, Arcturus, and Janssen will collaborate to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform. The agreement also includes an option to expand into other infectious and respiratory diseases. Terms of the agreement include Arcturus receiving an upfront cash payment, R&D support, and pre-clinical, development, and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.

Joseph Payne, President and CEO of Arcturus. “Arcturus’ expertise and intellectual property in the field of RNA medicines is complemented by Janssen’s broad capabilities in clinical development, regulatory affairs, and marketing. Together we aim to bring new treatments to patients who are suffering from Hepatitis B and potentially other infectious diseases.”

ADHD Stock Performance

Shares of Alcobra Ltd (NASDAQ:ADHD) are down over 36% for the year but are up almost 40% over the past month. In January ADHD stock plummeted over 50% when it was revealed that several law firms were pursuing class-action status for lawsuits over claims that corporate officers may have violated federal securities laws.

Interestingly, Alcobra Ltd (NASDAQ:ADHD) lists cash per share at $1.55 – more than today’s closing value.

Three firms follow Alcobra Ltd (NASDAQ:ADHD). One rates ADHD shares at a “Strong Buy”. one at a “Hold”, and one at a “Sell”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ADHD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Dextera Surgical Inc (NASDAQ:DXTR)

Bad Day for Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR) gapped down to open trading this morning, then struggled through the rest of the day, and ended down almost 25%. The company released no news that would account for the large move down. The NASDAQ market started lower today as well but ended down just 0.37%. Given that DXTR stock carries a -1.17 Beta, the shares clearly were more volatile than one would expect.

Dextera Surgical Inc (NASDAQ:DXTR)

About Dextera Surgical

Redwood City, CA-based Dextera Surgical Inc (NASDAQ:DXTR) is a global medical device company that develops proprietary stapling devices for minimally invasive surgical procedures. It primarily develops and commercializes MicroCutter 5/80, a cartridge-based micro cutter device used by for thoracic, pediatric, bariatric, colorectal, and general surgeons. The company also designs, manufactures, and markets automated anastomotic systems under the Cardica brand name for use by cardiac surgeons to perform coronary bypass surgery.

DXTR Stock

The medical device company has a market capitalization under $10 million. At the end of 2016, shares of Dextera Surgical Inc (NASDAQ:DXTR) bounced off the critical $1 per share level for three weeks before shooting above $2.25. A long slide in DXTR stock value then began in February of 2017 and shares broke through the psychologically important level of $0.50 in May. Since then DXTR stock has traded in a $0.15 – $0.40 range. Then, this week, DXTR stock hit their 52-week low of $0.13. 2017 has been tough for Dextera Surgical shareholders as DXTR shares have lost over 80% since January.

The company has an uncertain future and observers of the sector believe a sale or merger may be in the best interests of the company and shareholders. Existing shareholders are on the alert for another round of dilution as the company reportedly has just $0.05 in cash per share – that is a short runway, even for a nano-cap company. However, it should be noted that the company has been able to shrink its losses each year. In 2013, the per share loss was (-$3.95). Each year since then has seen a smaller loss and, for FY2017, the loss was a smaller (-$1.72). Also benefitting shareholders is the low share price which reflects a short-sale position on the stock’s float of less than 10%. Curiously, two investment firms rate DXTR stock as a “Strong Buy” and one rates the shares a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

TrovaGene Inc. (NASDAQ:TROV) PCM-075 Demonstrates Synergy

TrovaGene Inc. (NASDAQ:TROV) PCM-075 Demonstrates Synergy

TrovaGene Inc. (NASDAQ:TROV) shares gained 9.9% after the biotechnology company reported positive preclinical research, demonstrating synergy of PCM-075 in combination with Johnson & Johnson (NYSE:JNJ) drug Zytiga. Trial results indicate that when combined, the two appear to signal a previously unknown pathway.

TrovaGene Inc. (NASDAQ:TROV)

According To Trovagene Chief Scientific Officer, Mark Erlander, the unique combination could enhance the PCM-075 mechanism in arresting cells during mitosis with subsequent tumor cell death. The biotechnology company is investigating the adenosine triphosphate (ATP) competitive inhibitor for the treatment of metastatic castration-resistant prostate cancer.

“We previously completed a Phase 1 trial in metastatic solid tumor cancers, which provided a recommended Phase 2 dose and dosing schedule for PCM-075 in a combination regimen. We are working closely with key investigators to develop a Phase 2 clinical trial protocol with oral dosing of PCM-075 and abiraterone utilizing our existing solid tumor IND,” said CEO, Bill Welch.

Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has already granted an Orphan Drug Designation to PCM-075 for the treatment of acute myeloid leukemia. According to TrovaGene Inc. (NASDAQ:TROV) CEO, the designation underscores the agency desire to accelerate the development of the therapy given that AML affects nearly 20,000 people every year in the U.S.

The Orphan Drug Designation will allow TrovaGene to accelerate the development of PCM-075. The designation also allows the company up to seven years of market exclusivity upon regulatory approval. The company plans to initiate a Phase 1b/2 open-label trial to evaluate the safety and anti-leukemic activity of the candidate drug in combination with standard care.

TROV Stock Performance

TrovaGene Inc. (NASDAQ:TROV) has been a shadow of itself in the market this year as the stock is down by more than 50% as it continues to trade in a strong downtrend. Investor confidence on the tock appears to have hit all-time lows, seen by the stock struggling to rise above the $1 a share mark.

The company reported a net loss of (-$36.81) million in its most recent quarter as it continues to waver on its path to profitability. Arousing further investors’ concerns is the rate at which the company is burning cash. TrovaGene Inc. (NASDAQ:TROV) reportedly has $7.78 million in the bank compared to negative cash flows of $29.40 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TROV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Viking Therapeutics Inc (NASDAQ:VKTX)

Fireworks Continue for Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Inc (NASDAQ:VKTX) shares continued their strong upward trajectory today as the biotechnology firm’s stock rose over 25% in today’s trading to end the day at $2.60. Volume was heavy, almost ten times their normal daily average. The gains came in two waves, one right from the moment the market opened, and another buying wave began one hour before the market close.

A 2-day chart:

Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Recent Developments

Viking Therapeutics Inc (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. On October 4, 2017 VKTX shares jumped almost 9% when the company announced positive top-line results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal metabolic disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. X-ALD is estimated to occur in approximately 1 in 17,000 births. The results showed that 25 weeks of treatment with VK0214 led to robust effects on multiple very long chain fatty acids.

VKTX Stock

Performance for shares of Viking Therapeutics Inc (NASDAQ:VKTX) has been strong despite the lack of any sales – though that is not unusual for a clinical-stage biotechnology firm. Over the past year shares have risen over 126% and are up 134% for the past quarter. Today’s spike eclipsed the previous 52-week high of $2.44. In 2015 the company posted a per share loss of (-$3.68) but that shrank to a per share loss of (-$0.91) in 2016. However it should be noted that in 2016 the company diluted shareholder value. In 2015 there were 6.36 million shares outstanding and then in 2016 that number grew to 16.28 million.

Viking Therapeutics Inc (NASDAQ:VKTX) is covered by two analysts. Both rate VKTX shares as a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Receives FDA Protocol Guidance

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)

Shares of Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) gained 20.5% after the clinical stage biotechnology company received a final protocol guidance from the U.S. Food and Drugs Administration (FDA) for its lead compound Trans sodium crocetinate (TSC). The company is a preparing for Phase 3 trials of the compound in patients newly diagnosed with inoperable Glioblastoma multiforme, a type of brain cancer.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)

DFFN Stock Investor’s Reaction

The stock spiked by 35% as investors reacted to the favorable FDA ruling. However, the stock continues to trade in a downtrend after coming under pressure for the better part of the year. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) is down by more than 50% for the year.

Renewed investor interest comes on reports that the company responded to all outstanding points raised by the FDA on protocols for a protracted Phase 3 trial. The trial will compare the survival rates at two years for both the patients receiving the Trans sodium crocetinate and patients receiving chemotherapy and radiation as part of standard care.

“This Phase 3 study will focus on treating newly diagnosed GBM patients who have been judged by their medical team to be inoperable because of the size or location of the tumor. In Diffusion’s Phase 2 proof-of-concept trial, the inoperable GBM patients who were treated with TSC plus standard of care showed a nearly four-fold increase in survival at two years compared with standard of care patients only,” said CEO David Kelergis.

TSC Phase 3 Trial

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has already contracted a research organization to oversee to oversee the Phase 3 TSC trial as per the FDA standards. The company plans to carry out the trials in about 100 sites spread across the U.S. and Europe. Patient enrollment should begin before the end of the year.

Phase ½ clinical trial of TSC showed a 380% increase in survival rates at two years in inoperable patients. Trial results also indicate that 71% of the people treated by TSC were alive at one year compared to 61% of the people on historical group control.

A major difference between Phase ½ and Phase 3 will be the inclusion of TSC during Chemotherapy. In Phase ½, it was administered prior to radiation.

Glioblastoma is the most aggressive among known tumors and usually leads to death in one or two years. Standard care treatment consists of surgery to resect the tumor.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DFFN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE)

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) Drops After Pricing

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE)

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) shares fell 13.36% after the development stage biopharmaceutical company announced it had entered into a securities purchase agreement with certain investors. Pursuant to the agreement, the company has agreed to sell approximately $6.75 million worth of shares at a price of $0.875 a share.

AMPE Stock Investor Reaction

The offering will to close on or about October 18, 2017. Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) plans to use the net proceeds for working capital and general corporate purposes. Proceeds will also to be used for to fund the Ampion clinical trial.

The share offering appears to have spooked investors. The stock had been on an impressive run for the last month. Over the past month, AMPE is up by more than 100% as it continues its recovery from multi-year lows of $0.42 a share. However, the stock has underperformed the overall industry and is down by more than 10% compared to its January levels.

Ampion Clinical trials

Separately, Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) has completed enrollment and dosing of patients as part of a 12-week pivotal study of Ampion on patients with severe osteoarthritis of the knee (OAK). The primary endpoint of the study follows the Osteoarthritis Research Society International guidance.

“Announcing the close of enrollment so quickly speaks to the unmet medical need. We have found Ampion™ to be both safe and effective in the clinical development of over 1900 patients, many of whom have no other alternative treatment options,” said CEO Michael Macaluso.

Ampion is currently in late-stage study for the treatment of signs and symptoms of OAK. A recent randomized placebo-controlled trial focused on a subset of patients with severe OAK. The study examined the safety and efficacy of an intra-articular injection of Ampion compared to Saline.

Trial results indicate that a single injection of Ampion was well tolerated across all trials with patients showing significant response compared to saline.

Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) remains confident that the U.S. Food and Drug Administration (FDA) will approve Ampion as a reference product. If achieved, that will grant it 12 years of exclusivity. Ampio already has patent coverage in major jurisdictions of the likes of Europe, Brazil, Australia and Canada.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMPE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Directionless Akers Biosciences Inc (NASDAQ:AKER)

Akers Biosciences Inc (NASDAQ:AKER)

Akers Biosciences Inc (NASDAQ:AKER) stock is unchanged in the after-hours market after dropping over 15% today on heavy volume. No news was released that might account for the price drop. However AKER shares had been trending down or sideways since early April. The biotech firm hit its 52-week low of $0.70 in early October before jumping above $1.75 last week. Two days of losses followed that large move upwards.

Akers Biosciences Inc (NASDAQ:AKER)

About Akers Biosciences

West Deptford, NJ-based Akers Biosciences Inc (NASDAQ:AKER) was founded in 1989. The company develops in vitro diagnostic technologies that allow clinicians, and in some cases consumers, more quickly obtain health information. Their proprietary tests and sample preparation devices provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time. The company offers a alcohol breath detector, a breath ketone device for weight loss, and a device to measure oxidative stress among others.

In March Akers shares jumped when First Check Diagnostics, LLC placed an order with Akers Biosciences Inc (NASDAQ:AKER) for its cholesterol self-test. First Check Diagnostics LLC owns the First Check brand. Its products are distributed through such well-known stores such as CVS, Rite Aid, Target, and Kmart.

AKER Stock Review

Although AKER shares have a target price of $4, the shares have spent a considerable amount of time below $1 which is a threshold compliance level for the NASDAQ Market. A prolonged absence from a pricing above $1 may force the NASDAQ to issue a warning notice, and if unaddressed, a potential delisting. Akers Biosciences Inc (NASDAQ:AKER) stock has a 52-week high of $3.60 which was reached in late 2017. The 52-week low of $0.70 was hit in late September.

Sales and earnings have been inconsistent over the years. The company posted sales of just $1.6 million in 2012 and in 2014 hit a high of $4.4 million. However last year Akers posted a sales figure of only $3 million. Similarly, per share losses have been a regular event but there has been no trend that could provide investors with more confidence on the stock’s direction. In 2012, there was a per share loss of (-$2.24). That was followed by two years of lower losses but then in 2015 the loss expanded to (-$1.81), but then shrank to (-$0.61) for 2016. Unfortunately, the trend in the number of outstanding shares has been clear. In 2012 there were 1.14 million outstanding shares. That number has increased, and diluted shareholder value, every year. By 2016 the number of outstanding shares was posted at 5.43 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AKER and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Drop after Court Win

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Curiously, Orexigen Therapeutics, Inc. (NASDAQ:OREX) traded lower after a United States District Court issued a favorable ruling in a patent litigation case involving three patents for its obesity drug Contrave. Shares of the company fell 3.43% in Friday’s trading session to end the week at $1.97 a share.

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Orexigen Sell-Off

Friday’s sell-off strengthened a bearish tone that has seen the stock drop from $5.20 a share in February to current trading levels. While the stock is down by more than 60%, it is still above January’s trading levels.

Investor confidence has taken a hit following the termination of a collaboration agreement with Takeda. The agreement was for the commercialization of Orexigen’s obesity drug Contrave. The termination initially resulted in an increase in sales leading to net revenue increase, per unit, of 37%.

However, the increase was later offset by costs for commercialization of the drug. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has sought to change the situation by taking several steps to drive Contrave sales, in a bid to offset the costs. The company has already initiated speaker programs, as well as patient starter kits and promotional materials.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) faces an uphill task to boost its prospects in the already crowded obesity market. A variety of options exist from the likes of Vivus Inc., Novo Nordis,k and Arena Pharmaceuticals..

Contrave Patent Protection

The company is to provide a business update at the 2017 BIO investor forum on October 17, 2017. The Chief Executive Officer has already pointed out that the company is on a path to profitability by 2019. The executive made the remarks after the District Court extended the exclusivity of the company’s lead obesity drug through 2030.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has successfully defended its lead product, Contrave from Actavis which was planning to launch a generic version prior to the expiration of U.S Patents.

“Orexigen’s intent was to vigorously defend our intellectual property and we are very pleased with the Court’s decision upholding the validity of all of the patents involved in the case,” said Michael Narachi, President, and CEO of Orexigen. “The Court’s positive decision allows Orexigen to continue to fulfill its mission to provide innovative medicine to treat patients who are overweight or struggling with obesity.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OREX Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.